Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 July 2022 | Story Dr Nitha Ramnath | Photo Supplied
Leah Molatseli.


Leah Molatseli– alumna and Council member of the University of the Free State (UFS) – is the first African woman to be recognised by the American Bar Association in its list of Women of Legal Tech for her contribution and influence in the legal tech industry. A commitment to diversity is one of the core values of the American Bar Association, which the Law Practice Division aims to reinforce in the legal tech sector. Annually, talented women in the legal tech space are recognised for making an impact on legal tech.

A lawyer by profession, published legal tech author and speaker, as well as legal tech and innovation specialist, Molatseli uses technology and innovative means to empower and educate law professionals.  She is currently head of business development at Legal Interact, a South African law firm that provides technology solutions for the legal industry. 

Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, congratulated Molatseli on her achievement. “On behalf of the executive committee of the University of the Free State (UFS) and the university community, I would like to extend my warmest congratulations on being recognised by the American Bar Association for your contribution to the legal tech industry. Being the first African woman to be honoured in this way makes this accomplishment even more extraordinary. You are a trailblazer in your field in so many ways,” said Prof Petersen. 

Prof Petersen said, “The university, and the Faculty of Law in particular, is proud to be associated with you. We also appreciate your continued support to the institution. Your dedication and expertise inspire us all – I will continue to follow your professional journey, because I know there is much more in store”. Prof Petersen continued to thank Molatseli for contributing to the legal field in an innovative and contemporary manner. 

Molatseli is host of and guest speaker for various legal tech talks globally, as well as a guest lecturer at the University of Cape Town, where she develops and teaches legal tech innovation-related courses to the legal industry. A Mandela Washington fellow, as well as a Notre Dame alumna, she is a member of the Women in Tech South African Chapter, a country member for the Global Legal Tech Consortium, and is one of 2022’s ILTA’s Most Influential Women in Legal Tech honourees.  


News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept